Cited by 1,012Cancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesCutaneous Melanoma Detection and Management

The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.

Autoimmunity Correlates With Tumor Regression in Patients With Metastatic Melanoma Treated With Anti–Cytotoxic T-Lymphocyte Antigen-4

Open access

Attia, Peter, Phan, Giao Q., Maker, Ajay V., Robinson, Michael R., Quezado, Martha M., Yang, James C., Sherry, Richard M., Topalian, Suzanne L., Kammula, Udai S., Royal, Richard E., Restifo, Nicholas P., Haworth, Leah R., Levy, Catherine, Mavroukakis, Sharon A., Nichol, Geoff, Yellin, Michael J., Rosenberg, Steven A.·2005·Journal of Clinical Oncology

DOI 10.1200/jco.2005.06.205PMC PMC1473965

Open this paper in CoChat — free account Open PDF

Abstract

Purpose: Previously, we reported our experience treating 14 patients with metastatic melanoma using a fully human antibody to cytotoxic T-lymphocyte antigen-4 (anti–CTLA-4) in conjunction with peptide vaccination. We have now treated 56 patients to evaluate two different dose schedules of anti–CTLA-4 and to explore the relationship between autoimmunity and tumor regression. Patients and Methods: A total of 56 patients with progressive stage IV melanoma were enrolled onto the study. All had Karnofsky performance status ≥ 60% with no prior history of autoimmunity. Twenty-nine patients received 3 mg/kg anti–CTLA-4 every 3 weeks, whereas 27 received 3 mg/kg as their initial dose with subsequent doses reduced to 1 mg/kg every 3 weeks. In both cohorts patients received concomitant vaccination with two modified HLA-A*0201-restricted peptides from the gp100 melanoma-associated antigen, gp100:209-217(210M) and gp100:280-288(288V). Results: Two patients achieved a complete response (ongoing at 30 and 31 months, respectively) and five patients achieved a partial response (durations of 4, 6, 25+, 26+, and 34+ months, respectively), for an overall objective response rate of 13%. Tumor regression was seen in lung, liver, brain, lymph nodes, and subcutaneous sites. Of 14 patients with grade 3/4 autoimmune toxicity, five (36%) experienced a clinical response compared with only two responses in the 42 patients (5%) with no autoimmune toxicity (P = .008). There were no significant differences in response rate or toxicity between the two dose schedules. Conclusion: Administration of anti–CTLA-4 monoclonal antibody plus peptide vaccination can cause durable objective responses, which correlate with the induction of autoimmunity, in patients with metastatic melanoma.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1200/jco.2005.06.205

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Control of Regulatory T Cell Development by the Transcription Factor Foxp3
Hori, S., Nomura, T., & Sakaguchi, S. (2003) · Science · doi:10.1126/science.1079490 · Cited by 8,187
The Role of Tumoral FOXP3 on Cell Proliferation, Migration, and Invasion in Gastric Cancer
Zhang, L., Xu, J., Zhang, X., Zhang, Y., Wang, L., Huang, X., & Xu, Z. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000479442 · Cited by 4,090
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
An essential role for Scurfin in CD4+CD25+ T regulatory cells
Khattri, R., Cox, T., Yasayko, S.-A., & Ramsdell, F. (2003) · Nature Immunology · doi:10.1038/ni909 · Cited by 2,860
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766
Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4
Takahashi, T., Tagami, T., Yamazaki, S., Uede, T., Shimizu, J., Sakaguchi, N., Mak, T. W., & Sakaguchi, S. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.303 · Cited by 2,233
CTLA-4 can function as a negative regulator of T cell activation
Walunas, T. L., Lenschow, D. J., Bakker, C. Y., Linsley, P. S., Freeman, G. J., Green, J. M., Thompson, C. B., & Bluestone, J. A. (1994) · Immunity · doi:10.1016/1074-7613(94)90071-x · Cited by 2,222
CD4+CD25+ suppressor T cells: more questions than answers
Shevach, E. M. (2002) · Nature reviews. Immunology · doi:10.1038/nri821 · Cited by 2,097

Flagged first, then by citations

Show all 44 references

Sorted by citations

Items 701–800 of 1,000

Immunotherapy of melanoma
Hersey, P. (2010) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/j.1743-7563.2010.01269.x · Cited by 9
The “A, B and C” of Her-2 DNA vaccine development
Wei, W., Jacob, J. B., Radkevich-Brown, O., Whittington, P. J., & Kong, Y.-C. M. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0464-y · Cited by 9
Immunotherapy of Melanoma: An Update
Homsi, J., Grimm, J. C., & Hwu, P. (2010) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2010.09.004 · Cited by 9
The impact of biological agents interfering with receptor/ligand binding in the immune system.
Cianci, R., Cammarota, G., Raducci, F., & Pandolfi, F. (2005) · PubMed · Cited by 9
Immunomodulation in the treatment of haematological malignancies
Cesco-Gaspere, M., Morris, E. C., & Stauss, H. J. (2009) · Clinical and Experimental Medicine · doi:10.1007/s10238-009-0037-1 · Cited by 9
Systemic Therapy of Non-Resectable Metastatic Melanoma
Orouji, A., Goerdt, S., & Utikal, J. S. (2010) · Cancers · doi:10.3390/cancers2020955 · Cited by 9
The immunological era in melanoma treatment: new challenges for heat shock protein-based vaccine in the advanced disease
di Pietro, A., Tosti, G., Ferrucci, P. F., & Testori, A. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.605353 · Cited by 9
Lung Metastases
Ripley, R. T., & Rusch, V. W. (2014) · Elsevier eBooks · doi:10.1016/b978-1-4557-2865-7.00052-7 · Cited by 9
Therapie des metastasierten Melanoms
Rass, K., Tadler, D., & Tilgen, W. (2006) · Der Hautarzt · doi:10.1007/s00105-006-1195-7 · Cited by 9
Vogt-Koyanagi-Harada-like disease secondary to anticancer treatment: a multicentre case series
Urzúa, C. A., Olate-Pérez, Á., Anguita, R., Schlaen, A., Munk, M. R., Carreño, E., Garza-León, M., Sainz-de-la-Maza, M., Adán, A., Takeuchi, M., et al. (2025) · Eye · doi:10.1038/s41433-025-03720-6 · Cited by 8
Adaptive resistance in cancer immunotherapy
Yang, K. E., Yang, C., Xiong, K., Hao, J., & Ye, L. (2026) · Cellular and Molecular Immunology · doi:10.1038/s41423-026-01424-9 · Cited by 11
Ipilimumab: Showing Survival Benefit in Metastatic Melanoma
Minchom, A. R., Young, K., & Larkin, J. (2011) · Future Oncology · doi:10.2217/fon.11.105 · Cited by 8
Prognostic impact of thyroid dysfunctions on progression-free survival in patients with metastatic melanoma treated with anti-PD-1 antibodies
Frelau, A., Jali, E., Campillo‐Gimenez, B., Pracht, M., Porneuf, M., Dinulescu, M., Edeline, J., Boussemart, L., & Lesimple, T. (2021) · Melanoma Research · doi:10.1097/cmr.0000000000000739 · Cited by 8
Long-lasting complete response of metastatic melanoma to ipilimumab with analysis of the resident immune cells
Tsaknakis, B., Schaefer, I., Schwörer, H., Sahlmann, C., Thoms, K., Blaschke, M., Ramadori, G. P., & Cameron, S. (2013) · Medical Oncology · doi:10.1007/s12032-013-0813-3 · Cited by 8
Outcomes in Melanoma Patients Treated with BRAF/MEK-Directed Therapy or Immune Checkpoint Inhibition Stratified by Clinical Trial versus Standard of Care
Goldman, C., Tchack, J., Robinson, E. M., Han, S. W., Moran, U., Polsky, D., Berman, R. S., Shapiro, R. L., Ott, P. A., Osman, I., et al. (2017) · Oncology · doi:10.1159/000475715 · Cited by 8
Immune Checkpoint Inhibitor Associated Rheumatic Adverse Events: a Review of Their Presentations and Treatments
Ye, C., Jamal, S., Hudson, M., Fifi-Mah, A. V., & Roberts, J. (2019) · Current Treatment Options in Rheumatology · doi:10.1007/s40674-019-00131-z · Cited by 9
Public Adverse Event Data Insights into the Safety of Pembrolizumab in Melanoma Patients
Schaefer, A., Sachpekidis, C., Diella, F., Doerks, A., Kratz, A.-S., Meisel, C., Jackson, D., & Soldatos, T. G. (2020) · Cancers · doi:10.3390/cancers12041008 · Cited by 8
Exploring the immune-checkpoint inhibitors’ efficacy/tolerability in special non-small cell lung cancer (NSCLC) populations: focus on steroids and autoimmune disease
Passiglia, F., Cetoretta, V., Filippis, M. D., Napoli, V. M., & Novello, S. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-635 · Cited by 7
Bloodborne Cytokines for Predicting Clinical Benefits and Immune-Related Adverse Events in Advanced Non-Small Cell Lung Cancer Treated With Anti-Programmed Cell Death 1 Inhibitors
Oyanagi, J., Koh, Y., Sato, K., Teraoka, S., Tokudome, N., Hayata, A., Akamatsu, H., Ozawa, Y., Nakanishi, M., Ueda, H., et al. (2021) · Clinical Lung Cancer · doi:10.1016/j.cllc.2021.04.007 · Cited by 7
Ipilimumab, a Promising Immunotherapy with Increased Overall Survival in Metastatic Melanoma?
Pierard, G., Aubin, F., & Humbert, P. G. (2011) · Dermatology Research and Practice · doi:10.1155/2012/182157 · Cited by 8
Universal cancer vaccine
Lokhov, P. G., & Balashova, E. E. (2013) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.24300 · Cited by 8
Hazard Identification and Risk Assessment for Biologics Targeting the Immune System
Weir, A. B. (2008) · Journal of Immunotoxicology · doi:10.1080/15476910801897409 · Cited by 8
Targeted Therapy in Melanoma
Davies, M. A., Patel, S., & Kim, K. B. (2008) · Humana Press eBooks · doi:10.1007/978-1-60327-424-1_9 · Cited by 8
Interleukin‐2 Mastering Regulation in Cancer and Autoimmunity
Montero, E., ALONSO, L., Pérez, R., & Lage, A. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1381.026 · Cited by 8
Pitfalls or Promise in Prostate Cancer Immunotherapy—Which Is Winning?
Slovin, S. F. (2008) · The Cancer Journal · doi:10.1097/ppo.0b013e318161bffa · Cited by 8
Ipilimumab Pharmacotherapy in Patients with Metastatic Melanoma
Jeter, J., Cranmer, L. D., & Hersh, E. M. (2012) · Clinical Medicine Insights Oncology · doi:10.4137/cmo.s7245 · Cited by 7
Optimizing immune checkpoint blockade in metastatic uveal melanoma: exploring the association of overall survival and the occurrence of adverse events
Koch, E. A. T., Petzold, A., Dippel, E., Erdmann, M., Gesierich, A., Gutzmer, R., Hassel, J. C., Haferkamp, S., Kähler, K. C., Kreuzberg, N., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1395225 · Cited by 7
L’immunothérapie dans le mélanome
Routier, É., Robert, C., & Mateus, C. (2014) · Bulletin du Cancer · doi:10.1684/bdc.2014.2054 · Cited by 9
PD-1 inhibitor therapy causes multisystem immune adverse reactions: a case report and literature review
Yin, N., Liu, X., Ye, X., Song, W., Lu, J., & Chen, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.961266 · Cited by 7
Trial Design for Cancer Immunotherapy: A Methodological Toolkit
Saad, E., Coart, E., Deltuvaite-Thomas, V., Garcia-Barrado, L., Burzykowski, T., & Buyse, M. (2023) · Cancers · doi:10.3390/cancers15184669 · Cited by 8
Severe colitis while responding to ipilimumab in metastatic melanoma
Slingerland, M., Nortier, J. W. R., Veenendaal, R. A., & Kapiteijn, E. (2012) · Acta Oncologica · doi:10.3109/0284186x.2012.682630 · Cited by 7
Timeline: a decade of advances in immunotherapy
Pardoll, D. M. (2011) · Nature Medicine · doi:10.1038/nm0311-296 · Cited by 7
Treatment with Ipilimumab: A Case Report of Complete Response in a Metastatic Malignant Melanoma Patient
Addeo, A., & Rinaldi, C. R. (2013) · Case Reports in Oncology · doi:10.1159/000351834 · Cited by 7
Immunotherapy for Prostate Cancer: What's the Future?
Arlen, P. M., Dahut, W. L., & Gulley, J. L. (2006) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2006.03.003 · Cited by 7
Biology of Human Cutaneous Melanoma
Elias, E., Hasskamp, J. H., & Sharma, B. K. (2010) · Cancers · doi:10.3390/cancers2010165 · Cited by 7
Self-Recognition and Tumor Response to Immunotherapy
Ernstoff, M. S. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.95.029 · Cited by 7
pH-dependent dissociation from CTLA-4 in early endosomes improves both safety and antitumor activity of anti-CTLA-4 antibodies
Zhang, M., Li, J., Yan, K., Zhou, H., Mei, S., Wang, B., Li, D., Du, X., Liu, M., Zhang, P., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2422731122 · Cited by 6
Microbiota and immune-related adverse events in cancer immunotherapy
Schneider, S. M., Fan, C., Wang, Y., Jenq, R. R., & Watowich, S. S. (2026) · Nature reviews. Cancer · doi:10.1038/s41568-026-00921-3 · Cited by 6
Des avancées thérapeutiques majeures dans le traitement du mélanome métastatique
Mateus, C., & Robert, C. (2012) · Bulletin du Cancer · doi:10.1684/bdc.2012.1594 · Cited by 6
Risk of Pneumonitis Associated With Immune Checkpoint Inhibitors in Melanoma: A Systematic Review and Network Meta-Analysis
Sun, Y.-M., Li, W., Chen, Z., & Wang, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.651553 · Cited by 6
Colitis secundaria a ipilimumab: un nuevo reto para el gastroenterólogo
Mesonero, F., López–Sanromán, A., Madariaga, A., & Soria, A. (2015) · Gastroenterología y Hepatología · doi:10.1016/j.gastrohep.2015.06.005 · Cited by 6
Current Immunotherapeutic Strategies in Malignant Melanoma
Agostino, N. M., Ali, A., Nair, S., & Mosca, P. J. (2007) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2007.07.010 · Cited by 6
Peripheral tolerance limits CNS accumulation of CD8 T cells specific for an antigen shared by tumor cells and normal astrocytes
Calzascia, T., Loh, J. M. S., Berardino-Besson, W. D., Masson, F., Guillaume, P., Burkhardt, K., Herrera, P. L., Dietrich, P., & Walker, P. R. (2008) · Glia · doi:10.1002/glia.20715 · Cited by 6
Ipilimumab
Sanford, M. (2012) · BioDrugs · doi:10.2165/11208200-000000000-00000 · Cited by 6
Targeted therapeutic strategies in malignant melanoma
Dietrich, S., & Kasper, B. (2008) · Drug Discovery Today Disease Mechanisms · doi:10.1016/j.ddmec.2008.04.008 · Cited by 6
Unravelling the complexity of cancer–immune system interplay
Fraser, C. K., Brown, M. P., Diener, K. R., & Hayball, J. D. (2010) · Expert Review of Anticancer Therapy · doi:10.1586/era.10.66 · Cited by 6
Checkpoint inhibitors in the treatment of cutaneous malignant melanoma.
Lutzky, J. (2014) · PubMed · doi:10.3978/j.issn.2304-3865.2014.05.13 · Cited by 6
Markers for Anti-cytotoxic T-lymphocyte Antigen 4 (CTLA-4) Therapy in Melanoma
Postow, M. A., Yuan, J. D., Kitano, S., Lesokhin, A. M., & Wolchok, J. D. (2013) · Methods in molecular biology · doi:10.1007/978-1-62703-727-3_6 · Cited by 6
Ipilimumab in melanoma
Specenier, P. M. (2012) · Expert Review of Anticancer Therapy · doi:10.1586/era.12.132 · Cited by 6
Cumulative dermatologic toxicity with ipilimumab and vemurafenib responsive to corticosteroids
Ludlow, S. P., & Pasikhova, Y. (2013) · Melanoma Research · doi:10.1097/cmr.0000000000000018 · Cited by 6
Melanoma: 18F-FDG PET/CT for Response Assessment of Melanoma Following Immunotherapy
Sachpekidis, C., & Dimitrakopoulou‐Strauss, A. (2019) · Springer eBooks · doi:10.1007/978-3-030-31113-1_6 · Cited by 6
CLTA‐4 blockade in vivo promotes the generation of short‐lived effector CD8+ T cells and a more persistent central memory CD4+ T cell response
Hokey, D. A., Yan, J., Hirao, L. A., Dai, A., Boyer, J., Jure‐Kunkel, M., & Weiner, D. B. (2008) · Journal of Medical Primatology · doi:10.1111/j.1600-0684.2008.00324.x · Cited by 6
Tumor Infiltrating Regulatory T Cells: Tractable Targets for Immunotherapy
Khan, A. R., Dovedi, S. J., Wilkinson, R. W., & Pritchard, D. (2010) · International Reviews of Immunology · doi:10.3109/08830185.2010.508854 · Cited by 6
Moving forward with immunotherapy: the rationale for anti-CTLA-4 therapy in melanoma
Margolin, K. A. (2008) · Community Oncology · doi:10.1016/s1548-5315(11)70470-3 · Cited by 6
Immunotherapy and Cancer Therapeutics: Why Partner?
Emens, L. A., & Jaffee, E. M. (2007) · Elsevier eBooks · doi:10.1016/b978-012372551-6/50076-6 · Cited by 6
Immunotoxicological Concerns for Vaccines and Adjuvants
Kaplanski, C. V., Lebron, J., Wolf, J. J., & Ledwith, B. J. (2008) · Wiley eBooks · doi:10.1002/9780470386385.ch18 · Cited by 5
Clinical pharmacologic aspects of immune checkpoint inhibitors in cancer therapy
Kim, K., & Jung, H. (2016) · Translational and Clinical Pharmacology · doi:10.12793/tcp.2016.24.1.7 · Cited by 5
Effect of glucocorticoids for the management of immune-related adverse events on outcome in melanoma patients treated with immunotherapy—a retrospective and biomarker study
Svedman, F. C., Liapi, M., Månsson‐Broberg, A., Chatzidionysiou, K., & Brage, S. E. (2024) · Immuno-Oncology Technology · doi:10.1016/j.iotech.2024.100713 · Cited by 5
Tribulations or triumphs in prostate cancer immunotherapy: on the road to victory?
Slovin, S. F. (2008) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.8.3.465 · Cited by 5
Melanoma Vaccines and Modulation of the Immune System in the Clinical Setting: Building from New Realities
Rowdo, F. P. M., Lacreu, M. L., & Mordoh, J. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00103 · Cited by 5
Autoimmune diseases and hypersensitivities improve the prognosis in ER-negative breast cancer
Einefors, R., Kogler, U., Ellberg, C., & Olsson, H. L. (2013) · SpringerPlus · doi:10.1186/2193-1801-2-357 · Cited by 5
Real-world safety and efficacy of nivolumab for ≥ 2nd line treatment of metastatic renal cell carcinoma: A retrospective cohort study in Croatia, Hungary, and Malta
Vrdoljak, E., Magri, C., Gamulin, M., Bošković, L., Omrčen, T., Bajić, Ž., Dienes, T., & Géczi, L. (2020) · Neoplasma · doi:10.4149/neo_2020_200512n519 · Cited by 5
Systemic and Liver-Directed Therapies in Metastatic Uveal Melanoma: State-of-the-Art and Novel Perspectives
Comito, F., Marchese, P. V., Ricci, A. D., Tober, N., Peterle, C., Sperandi, F., & Melotti, B. (2021) · Future Oncology · doi:10.2217/fon-2021-0318 · Cited by 5
Cancer Immunotherapy
White, R. L., & Amin, A. (2011) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2011.01.010 · Cited by 5
Moderate Colitis Not Requiring Intravenous Steroids Is Associated with Improved Survival in Stage IV Melanoma after Anti-CTLA4 Monotherapy, But Not Combination Therapy
Anstadt, E. J., Chu, B. K., Yegya‐Raman, N., Han, X., Doucette, A. G., Poirier, K., Mohiuddin, J. J., Maity, A. M., Facciabene, A., Amaravadi, R. K., et al. (2022) · The Oncologist · doi:10.1093/oncolo/oyac108 · Cited by 5
The avidity of tumor‐specific T cells amplified by a plasmacytoid dendritic cell‐based assay can predict the clinical evolution of melanoma patients
Charles, J., Chaperot, L., Revol, B., Baudin, M., Mouret, S., Hamon, A., Leccia, M. ‐., Plumas, J., & Aspord, C. (2017) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12618 · Cited by 5
An Update on Immune Checkpoint Inhibitor-related Hypophysitis
Mortensen, M. J., Oatman, O. J., Azadi, A., Fonkem, E., & Yuen, K. C. J. (2020) · US Endocrinology · doi:10.17925/use.2020.16.2.117 · Cited by 5
Metastatic melanoma: an AJCC review
Agarwala, S. S. (2008) · Community Oncology · doi:10.1016/s1548-5315(11)70491-0 · Cited by 5
Immunotherapy for genitourinary cancer
Cattrini, C., Dellepiane, C., Cavo, A., Buzzatti, G., Tolomeo, F., Messina, C. G. M., & Boccardo, F. (2016) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000376 · Cited by 5
General Principles of Tumor Immunotherapy
Kaufman, H. L., & Wolchok, J. D. (2007) · Springer eBooks · doi:10.1007/978-1-4020-6087-8 · Cited by 15
Molecular Mechanisms of Immune Checkpoints as an Immunotherapy Tool in Hematological Malignancies
Gezici, S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-15717-2.00035-4 · Cited by 4
Immune checkpoint inhibitor-associated new-onset hypophysitis: a retrospective analysis using the FAERS
Lu, D., Yao, J., Yuan, G., Gao, Y., Zhang, J., & Guo, X. (2024) · Endocrine · doi:10.1007/s12020-024-03949-3 · Cited by 4
Immune Co-signaling to Treat Cancer
Callahan, M. K., Wolchok, J. D., Allison, J. P., & Sharma, P. (2012) · Springer eBooks · doi:10.1007/978-1-4614-4732-0_8 · Cited by 4
Immunotherapy: Shifting the Balance of Cell-Mediated Immunity and Suppression in Human Prostate Cancer
Tucker, J. A., Jochéms, C., Gulley, J. L., Schlom, J., & Tsang, K. Y. (2012) · Cancers · doi:10.3390/cancers4041333 · Cited by 4
Mélanome — Thérapeutique par les médications : anticorps anti-CTLA-4 et anti-PD1
Robert, C., & Mateus, C. (2014) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/s0001-4079(19)31343-3 · Cited by 4
Sicca Syndromes
Warner, B. M., & Baer, A. N. (2021) · Springer eBooks · doi:10.1007/978-3-030-56824-5_7 · Cited by 4
Pathologic Response of the Gastrointestinal Tract to Toxicants
Sakamoto, K. (2010) · Elsevier eBooks · doi:10.1016/b978-0-08-046884-6.00856-3 · Cited by 4
Cytokine therapy for renal cell cancer: the evolving role of immunomodulation
Leary, A. F., Larkin, J., & Pickering, L. M. (2011) · Therapy · doi:10.2217/thy.11.26 · Cited by 4
The Role of Regulatory T Cells and Indoleamine-2,3-dioxygenase in Brain Tumor Immunosuppression
Dey, M., Chang, A. L., Miska, J. M., Qiao, J., & Lesniak, M. S. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-802420-1.00003-x · Cited by 4
Role of Regulatory T Cells in Tumor-Bearing Mice Treated with Allo-Hematopoietic Stem Cell Transplantation Plus Thymus Transplantation
Hosaka, N. (2018) · Journal of Immunology Research · doi:10.1155/2018/7271097 · Cited by 4
Nobel Prize for immune checkpoint inhibitors, understanding the immunological switching between immunosuppression and autoimmunity
Motofei, I. G. (2021) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2020243 · Cited by 5
Immune Signatures Associated with the Cancer Bearing State
Critchley-Thorne, R. J., Yu, H., & Lee, P. P. (2010) · Springer eBooks · doi:10.1007/978-1-4419-7219-4_11 · Cited by 4
Is Antigen Specificity the Key to Efficient Adoptive T-Cell Therapy?
Labarrière, N., Khammari, A., Lang, F., & Dréno, B. (2011) · Immunotherapy · doi:10.2217/imt.11.16 · Cited by 5
El potencial de la inmunomodulación con anticuerpos monoclonales anti-CD137 (4-1BB) para terapia de enfermedades malignas e infecciones virales crónicas
Alfaro, C., Murillo, O., Tirapu, I., Azpilicueta, A., Huarte, E., Arina, A., Arribillaga, L., Perez‐Gracia, J. L., Bendandi, M., Prìeto, J., et al. (2006) · Anales del Sistema Sanitario de Navarra · doi:10.4321/s1137-66272006000100007 · Cited by 4
Dawn of Monitoring Regulatory T Cells in (Pre-)clinical Studies: Their Relevance Is Slowly Recognised
de Wolf, A. C. M. T., Herberts, C. A., & Hoefnagel, M. H. N. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.00091 · Cited by 4
Translational Research in Melanoma
Tsai, S., & Sabel, M. S. (2008) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2007.12.003 · Cited by 4
Melanoma vaccines – they should work
Danson, S. J., & Lorigan, P. C. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl055 · Cited by 4
Final clinical analysis of pre-operative ipilimumab and nivolumab in locally advanced urothelial cancer and exploration of tumor-draining lymph node composition: The NABUCCO trial
Stockem, C. F., van Dorp, J., van Dijk, N., Vis, D. J., Harkes, R., van den Broek, B., Alkemade, M., Broeks, A., Hendricksen, K., Boellaard, T. N., et al. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.115731 · Cited by 3
Autoimmunity in the era of immune checkpoint inhibitors: the evolving epidemiology of autoimmune diseases and the possible impact of COVID-19
Mahroum, N., Elsalti, A., Alsharif, M., Jabri, A., & Ouban, A. (2026) · Autoimmunity Reviews · doi:10.1016/j.autrev.2026.104002 · Cited by 3
Towards a therapeutic breast cancer vaccine: the next steps
Emens, L. A. (2005) · Expert Review of Vaccines · doi:10.1586/14760584.4.6.831 · Cited by 3
New-onset toxicity with programmed death-1 inhibitor rechallenge
Ludlow, S. P., Andrews, S., Pasikhova, Y., & Hill, E. D. (2016) · Melanoma Research · doi:10.1097/cmr.0000000000000259 · Cited by 3
Antibodies to Stimulate Host Immunity
Callahan, M. K., Postow, M. A., & Wolchok, J. D. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-394296-8.00019-1 · Cited by 3
Dermatologic adverse events associated with targeted therapies for melanoma
Scarpato, L., Festino, L., Vanella, V., Madonna, G., Mastroianni, M., Palla, M., & Ascierto, P. A. (2021) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.1986000 · Cited by 3
Non-Neoplastic Pathology of the Gastrointestinal Tract
(2020) · Cambridge University Press eBooks · doi:10.1017/9781316823026 · Cited by 3
Endocrine Adverse Events Related To Immune Checkpoint Inhibitor Treatment: Relationship Between Antibodies and Severity of Thyroid Dysfunction
González, M. M., Sanz-Pastor, A. G., Áñez, R., Torrecilla, N. B., Moreno, D. M., Fernández, L. G., Rivas, A. M., Guerra, A. L., Alvarez, R. M., Arranz, J. Á., et al. (2024) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/0118715303280679240206100137 · Cited by 3
Cardiovascular toxicity with CTLA‐4 inhibitors in cancer patients: A meta‐analysis
Liu, H., Fu, L., Jin, S., Ye, X., Chen, Y., Pu, S., & Xue, Y. (2024) · Cancer Innovation · doi:10.1002/cai2.116 · Cited by 3
Side Effects of Cancer Immunotherapy with Checkpoint Inhibitors
Festino, L., & Ascierto, P. A. (2017) · Springer eBooks · doi:10.1007/978-3-319-62431-0_33 · Cited by 3
Malignes Melanom
Hallermann, C., Atzpodien, J., Klein, M., Krause‐Bergmann, A., Brodner, G., Strittmatter, G., Brunner, G., & Schulze, H.-J. (2009) · best practice onkologie · doi:10.1007/s11654-009-0186-4 · Cited by 3
Ipilimumab-induced colitis: A new challenge for gastroenterologists
Mesonero, F., López–Sanromán, A., Madariaga, A., & Soria, A. (2016) · Gastroenterología y Hepatología (English Edition) · doi:10.1016/j.gastre.2016.02.016 · Cited by 3
Melanoma: Immunotherapy in Advanced Melanoma and in the Adjuvant Setting
Eggermont, A. M. M., & Robert, C. (2017) · Springer eBooks · doi:10.1007/978-3-319-62431-0_34 · Cited by 3

Authors: Attia, P., Phan, G. Q., Maker, A. V., Robinson, M. R., Quezado, M. M., Yang, J. C., Sherry, R. M., Topalian, S. L., Kammula, U. S., Royal, R. E., Restifo, N. P., Haworth, L. R., Levy, C., Mavroukakis, S. A., Nichol, G., Yellin, M. J., & Rosenberg, S. A.
Affiliations: National Institutes of Health (US)
ORCID: Phan, Giao Q.
Maker, Ajay V.
Robinson, Michael R.
Quezado, Martha M.
Yang, James C.
Sherry, Richard M.
Topalian, Suzanne L.
Kammula, Udai S.
Restifo, Nicholas P.
Mavroukakis, Sharon A.
Yellin, Michael J.
Rosenberg, Steven A.
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2005-09-01
Volume: 23
Issue: 25
Pages: 6043-6053
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2005.06.205
PMC: PMC1473965
OpenAlex: W2151507811
Cited by: 1,012
References: 44
Citations by year: 2026: 6 · 2025: 15 · 2024: 18 · 2023: 17 · 2022: 31 · 2021: 45 · 2020: 81 · 2019: 46 · 2018: 45 · 2017: 55 · 2016: 60 · 2015: 64 · 2014: 49 · 2013: 63 · 2012: 43
FWCI: 30.93
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health (Z99 CA999999)
National Cancer Institute (Z01BC010763)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
Keywords: metastatic melanoma, anti-CTLA-4 monoclonal antibody, CTLA-4 blockade, autoimmunity, autoimmune toxicity, tumor regression, peptide vaccination, gp100, dosing regimen, immune checkpoint inhibitors, objective response rate
MeSH terms: Adult, Aged, Antigens, Differentiation, Drug Administration Schedule, Female, Humans, Immunosuppressive Agents, Injections, Intravenous, Male, Melanoma, Middle Aged, Prognosis, Skin Neoplasms, Autoimmunity, Antigens, CD, Treatment Outcome, Cancer Vaccines, CTLA-4 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Autoimmunity Correlates With Tumor Regression in Patients With Metastatic Melanoma Treated With Anti–Cytotoxic T-Lymphocyte Antigen-4

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks